Home / Stocks / AKRO

AKRO insider trading

Akero Therapeutics, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
2
Bought · 24 mo
$18.4M
Buys · last 90 days
0 · $0
Most recent buy
2025-03-27

Recent insider filings

FiledInsiderTypeSharesPriceValue
2025-10-14Cheng Andrew
President and CEO
Sold30,000$53.98$1.6M
2025-06-09Rolph Timothy
Chief Scientific Officer
Sold25,000$55.04$1.4M
2025-04-11Cheng Andrew
President and CEO
Sold30,000$35.23$1.1M
2025-03-27Graham G. Walmsley
Director
Bought200,000$43.94$8.8M
2025-03-12Cheng Andrew
President and CEO
Sold28,784$41.75$1.2M
2025-03-05Young Jonathan
Chief Operating Officer
Sold38,553$45.07$1.7M
2025-02-07Graham G. Walmsley
Director
Bought200,000$48.00$9.6M
2025-01-31Yale Catriona
Chief Development Officer
Sold27,340$57.02$1.6M
2025-01-31Yale Catriona
Chief Development Officer
Sold25,907$55.15$1.4M
2025-01-29Cheng Andrew
President and CEO
Sold24,242$54.56$1.3M
2024-11-05Young Jonathan
Chief Operating Officer
Sold34,943$31.25$1.1M
2024-11-05Cheng Andrew
President and CEO
Sold81,280$31.47$2.6M
2024-10-18Cheng Andrew
President and CEO
Sold63,313$31.53$2.0M
2024-10-16Young Jonathan
Chief Operating Officer
Sold40,000$30.15$1.2M

Most active insider buyers

InsiderRoleBuysTotal bought
Graham G. WalmsleyDirector2$18.4M

See AKRO on the chart

Every insider buy and sell for AKRO plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.